Why Generic Drugmakers Are Sometimes Paid Not to Compete
Brand-name manufacturers can pay generic firms to delay entering the market, preserving higher prices rather than merely rewarding pharmaceutical innovation. Proposed responses included attacking pay-for-delay arrangements, permitting safe imports from Canada, and allowing Medicare to negotiate as a major buyer.
- Pay-for-delay incentives keep cheaper generics out of the market.
- The practice can produce both higher prices and less innovation.
- US consumers pay substantially more than international counterparts for many drugs.
- Medicare purchasing power could place broader downward pressure on prices.
“we see in the evidence of these pay for delay UH schemes that it produces both of those outcomes, less innovation and higher prices.”
“you are likely to pay two and a half times as much for the same prescription drug than your international counterpart.”